Paris Abstracts cost-effectiveness ratio (ICER) for the comparison of imiquimod versus no treatment was 1,227 PLN per gained complete clearance assessed clinically and histologically, and 1,138 PLN per gained complete clearence assessed only histologically. CONCLU-SIONS: Imiquimod is more effective and more expensive than no treatment in patients with superficial basal cell carcinoma and contraindication to surgical intervention and cryotherapy. ICER value is below the acceptable threshold, therefore imiquimod therapy is considered as cost-effective treatment in Poland.
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Mapi Values, Houten, The Netherlands, 2 Mapi Values, Bollington, UK, 3 Nycomed, Taastrup, Denmark, 4 Mapi Values, Boston, MA, USA OBJECTIVES: A decision-analysis model parameterised for Scotland was used to evaluate the cost-effectiveness of intranasal fentanyl spray (INFS, Instanyl ® ) compared with oral transmucosal fentanyl citrate lozenge (OTFC, Actiq ® ) and oral transmucosal fentanyl buccal tablet (FBT, Effentora ® ) for the treatment of BTCP. METHODS: The model estimated costs and benefits associated with INFS, OTFC and FBT. Relative estimated costs and benefits associated with INFS, OTFC and FBT. Relative Relative analgesic efficacy of the interventions was derived from a meta-analysis of six randomised controlled trials. The percentage of BTCP avoided was estimated from the pain intensity (PI) course of a BTCP episode with and without treatment. Resource use and quality of life gains were estimated based on reductions in PI. The relationship between PI and utility was derived from a time-trade off study in the UK general population. Resource use and unit cost data were obtained from the literature and validated by clinical experts. Uncertainty in the source data was incorporated by Uncertainty in the source data was incorporated by means of one-way sensitivity analyses, probabilistic sensitivity analyses and different scenario analyses. RESULTS: For the base-case scenario, 3 BTCP episodes/day, a background PI of 2, a time-horizon of 365 days and equal prices for INFS and OTFC irrespective of dosage were assumed. With INFS, 55% of BTCP (95% Uncertainty Interval: 45-66%) was avoided, greater than expected with OTFC (29%; 21-39%) or FBT (31%; 25-39%). INFS was dominant versus OTFC and cost-effective versus FBT. Despite the uncertainty in the source data, there is a Despite the uncertainty in the source data, there is a 99% probability that INFS is the most cost-effective intervention. Sensitivity and scenario analyses did not change the main conclusion. CONCLUSIONS: Greater efficacy of INFS in pain reduction is expected to reduce medical resource use and result in cost-savings for health care providers and quality of life gains for patients. INFS is a cost-effective treatment for BTCP compared with OTFC and FBT in Scotland.
PCN102 102 COST EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2 VE BREAST CANCER IN ITALY UTILIZING FOLLOW UP DATA
Giuliani G 1 , Ray JA 2 , Urspruch A 2 1 Roche S.p.A. Italy, Monza, Italy, 2 F. Hoffmann-La Roche Ltd., Basel, Switzerland OBJECTIVES: Based on results from the HERceptin Adjuvant Trial (HERA) with a median follow-up time of 1 year, trastuzumab is licensed and reimbursed for the treatment of HER2 early breast cancer (EBC) in Italy since 2006. As the risk of recurrence reduces overtime, hazard ratios in breast cancer trials usually increase as more follow-up data is available. Longer term follow-up data were recently reported for 2 and 4 years, the latter though being heavily confounded by extensive cross-over of the HERA comparator arm and hence unusable. The objective of this analysis was therefore to determine the cost effectiveness of 1-year treatment with trastuzumab vs observation, based on results from the 2-year follow up data. METHODS: A published Markov model based on the initial HERA results was revised and updated to incorporate the hazard ratios from the 2-year follow up data to reflect trastuzumab's impact on disease progression. The treatment effect reported was applied for the first 4 years of the model. An Italian health care payer perspective was adopted. Medication and acquisition costs were taken from published sources whereas health state and event costs were derived from costing study conducted in Tuscany. A lifetime horizon was chosen. Incremental cost-effectiveness ratios were expressed as cost per quality adjusted life year (QALY). Costs and QALYs were discounted at 3.0% p.a. Sensitivity analyses were performed. RESULTS: The analysis showed that after completion of adjuvant chemotherapy, treatment with trastuzumab resulted into additional 1.81 life years and 1.62 QALYS gained per patient compared to observation only, at an incremental mean total cost of a18,022. The ICER was estimated at a11,131/QALY, which is well in line with previously published analyses. CONCLUSIONS: Using more recent data from the HERA trial, Trastuzumab was determined to remain a cost effective treatment option for HER2 ve EBC in the Italian setting. chronic lymphocytic leukaemia (CLL) with with rituximab added to chemotherapy, we evaluated the cost-effectiveness of rituximab in combination with commonly used chemotherapy regimen of fludarabine plus cyclophosphamide (R-FC) versus fludarabine plus cyclophosphamide (FC) from the perspective of the Spanish national health care system. METHODS: A three stage Markov model including progression-free survival (PFS), progression state and mortality was developed using published results from the randomized clinical trial CLL-8 evaluating PFS in patients with CLL. Rates of disease progression were derived CLL. Rates of disease progression were derived . Rates of disease progression were derived from a Weibull model, mortality rates were obtained from Kaplan-Meier and Spanish age-specific mortality tables. Patient elicited utilities were applied to PFS and progressed health states. The cost of drugs, supportive care, and quality-adjusted life years (QALY) were estimated over a period of 10 years, the median survival for CLL, and discounted at 3.5 per annum. Univariate and probabilistic (Monte Carlo simulation) sensitivity analysis were performed. RESULTS: The addition of rituximab to chemotherapy increased life-years gained (LYG) and QALYs by 0.669 and 0.617 years per patient, respectively, compared to chemotherapy alone. The incremental cost per LYG and QALY gained was a17,726 and a19,220, respectively. Cost-effective results were obtained with Monte Carlo simulation. Univariate sensitivity analyses indicated the results were robust, and most sensitive to time horizon, with a threshold value at year 7, from which the R-FC regimen is cost-effective. CONCLUSIONS: The model demonstrated that the addition of rituximab to fludarabine plus cyclophosphamide (FC) regimen increased life and quality-adjusted life expectancy and is a cost-effective first-line treatment option for patients with chronic lymphocytic leukaemia.
PCN103 PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FLUDARABINE-CYCLOPHOSPHAMIDE REGIMEN IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS IN SPAIN

PCN104
COST-EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER IN CHINA
Chen W 1 , Sheng F 2 , Qiao N 1 1 Fudan University, Shanghai, China, 2 Shanghai Roche Pharmaceuticals Ltd, Shanghai, China OBJECTIVES: The objective of the study was to evaluate the cost-effectiveness of erlotinib compared to docetaxel for the treatment of advanced non small cell lung cancer (NSCLC) in China. METHODS: A Markov health-state model was designed to estimate the direct medical costs and outcomes (life years and QALYs gained) of treating advanced NSCLC. The model included three health states-progression free survival (PFS), post progression free survival (PPF) and death. The evolution of a cohort of patients was simulated along 2 years with monthly cycles. Survival and time to progression were retrieved from 2 pivotal clinical trials. From the perspective of China's health insurance system, resource use was calculated based on a questionnaire survey from clinical expert panels. A discounting rate at 3% was used to discount medical costs happening at different years. A univariate sensitivity analysis was performed to understand the key drivers and general sensitivity of the model. RESULTS:
The model results showed that the utilization of erlotinib treatment in NSCLC can prolong 0.047 QALYs (0.038 life years), compared to the docetaxel treatment. The total cost per patient was lower with erlotinib (US$23,351) than with docetaxel (US$24,846). The lower cost and better efficacy associated with erlotinib makes it a dominant treatment strategy in comparison to docetaxel. CONCLUSIONS: According to this model, erlotinib is more cost-effective than docetaxel in treating advanced NSCLC, with savings for the China's health insurance system.
